DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of the Application
Applicant's election without traverse of Group II, drawn to a method of preventing or treating a disease associated with tissue damage by administering a MST1/2 protein kinase inhibitor of formula II, and the species, ischemic stroke and compound II-1, in the reply filed 7/1/25 is acknowledged.
Claims 1-4, 6-18, 21, 29-30 are pending. Claim 4, 6-15 have been withdrawn from further consideration as being drawn to a non-elected species. Claims 1-3, 16-18, 21, 29-30 are examined herein insofar as they read on the elected invention and species.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1-3, 16-18, 21, 29-30 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Deng et al. (WO 2017/148406 A1, machine translation).
Deng et al. teaches methods of treating ischemia diseases by administering a compound that inhibits the MST1/2 protein kinase activity according to formula I (abstract). A preferred compound is compound II-1 (same structure as the species election) in Table 2 on page 59. A preferred disease is stroke (page 53). Prophylaxis or prevention of the disease or its symptoms to a subject that has not yet been diagnosed is also taught (page 29, first paragraph). The unit dosage form can be a capsule or tablet and can be between 0.1 to 1000 mg or more (page 30, 5th full paragraph). Figures 2 and 3 show that compound II-1 was administered at a dose of 1 mg/kg body weight.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yong S. Chong whose telephone number is (571)-272-8513. The examiner can normally be reached Monday to Friday: 9 AM to 5 PM EST.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam Milligan, can be reached at (571)-270-7674. The fax phone number for the organization where this application or proceeding is assigned is (571)-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at (866)-217-9197 (toll-free).
/Yong S. Chong/Primary Examiner, Art Unit 1623